Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Department of Dermatology Government Medical College Baramulla
Department of Pharmaceutical Sciences University of Kashmir
Dr GN Bader
Dr Parvaiz Anwar Rather
Zahid Ashraf
Eligibility
Inclusion criteria
Inclusion criteria: 1. All the patients diagnosed with Vitiligo of all age groups and of either sex visiting OPD of the Dermatology Department and who gave consent during the study period were included in this study. 2. Confirmed vitiligo diagnosis by a healthcare professional through clinical examination, dermoscopy, or biopsy (specific methodology may vary based on study design). 3. Consent to participate in the study procedures, including surveys, interviews, physical examinations, blood tests, or imaging studies (specific procedures depend on study focus). 4. No age or demographic restrictions unless studying specific populations (e.g., pregnant women, above 70 years). 5. Age of consent (e.g., 18+) and ability to complete psychological assessments. 6. Diagnosis of a specific co-occurring disorder confirmed through medical records or additional diagnostic procedures. 7. Specific disease type, severity, and age range suitable for the investigated treatment modality.
Exclusion criteria
Exclusion criteria: 1. Patients not giving consent to participate in the study. 2. Mimicking Conditions: Presence of skin conditions that could mimic vitiligo (e.g., piebaldism, post-inflammatory hypopigmentation). 3. Self-Reported Vitiligo: Individuals lacking a professional diagnosis of vitiligo. 4. Cognitive/Psychiatric Conditions: Severe cognitive or psychiatric conditions that could significantly impact data collection or interpretation. 5. Medical Conditions: Presence of medical conditions that could confound study results or pose safety risks (e.g., chronic infections, certain medications). 6. Treatment Contraindications: Known contraindications to the specific treatment being investigated (e.g., allergies, specific medical conditions). 7. Ongoing Trials: Participation in other clinical trials that could interfere with study results. 8. Individuals with language barriers that impede effective communication may be excluded. 9. Pregnant or breastfeeding women may be excluded depending on the specific treatment safety data. 10. Uncertain diagnoses of vitiligo or co-occurring disorders may lead to exclusion to ensure study accuracy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improved diagnosis and management strategies for healthcare professionals dealing with Vitiligo patients. Timepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Enhanced psychological support and interventions to address the emotional and social impact of Vitiligo.Timepoint: 6 months;Evaluation of treatment options to determine their effectiveness, patient satisfaction, and areas for improvement. Timepoint: 6 months;Identification of potential Comorbidities and associated disorders to guide comprehensive patient care.Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr GN Bader
Department of Pharmaceutical Sciences, University of Kashmir
Outcome results
None listed